Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

被引：14

作者：

Abeykoon, Jithma P. ^{[1
]}

Vaxman, Julia ^{[1
]}

Patel, Sanjay V. ^{[2
]}

Kumar, Shaji ^{[1
]}

Malave, Gabriella C. ^{[1
]}

Young, Kimberly S. ^{[1
]}

Ailawadhi, Sikander ^{[3
]}

Larsen, Jeremy T. ^{[4
]}

Dispenzieri, Angela ^{[1
]}

Muchtar, Eli ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Kourelis, Taxiarchis ^{[1
]}

Leung, Nelson ^{[1
]}

Warsame, Rahma ^{[1
]}

Go, Ronald S. ^{[1
]}

Bergsagel, Leif ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Gertz, Morie A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[2] Mayo Clin, Dept Ophthalmol, Rochester, MN USA

[3] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Div Hematol, Scottsdale, AZ USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 01期

关键词：

antibody-drug conjugate; B-cell maturation antigen; monoclonal gammopathy; ANTIBODY; DRUG;

D O I：

10.1111/bjh.18298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

引用

页码：95 / 99

页数：5

共 50 条

[21] Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Farooq, Asim, V
Degli Esposti, Simona
Popat, Rakesh
Thulasi, Praneetha
Lonial, Sagar
Nooka, Ajay K.
Jakubowiak, Andrzej
Sborov, Douglas
Zaugg, Brian E.
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Opalinska, Joanna
Baron, January
Piontek, Trisha
Byrne, Julie
Gupta, Ira
Colby, Kathryn
OPHTHALMOLOGY AND THERAPY, 2020, 9 (04) : 889 - 911
[22] Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Richardson, Paul G.
Lee, Hans C.
Abdallah, Al-Ola
Cohen, Adam D.
Kapoor, Prashant
Voorhees, Peter M.
Hoos, Axel
Wang, Karrie
Baron, January
Piontek, Trisha
Byrne, Julie
Richmond, Scott
Jewell, Roxanne C.
Opalinska, Joanna
Gupta, Ira
Lonial, Sagar
BLOOD CANCER JOURNAL, 2020, 10 (10)
[23] Belantamab mafodotin Antibody-drug conjugate targeting B-cell maturation antigen (BCMA) Treatment of multiple myeloma
Routledge, D.
DRUGS OF THE FUTURE, 2020, 45 (12) : 865 - 875
[24] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Degli Esposti, Simona
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
[25] Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?
Chauvier, Jason
Trone, Marie-Caroline
Gain, Philippe
Ollier, Edouard
Robert, Pierre-Yves
Arnould, Louis
Bourcier, Tristan
Cassagne, Myriam
Maalouf, Jean
Martel, Arnaud
Hoffart, Louis
Rousseau, Antoine
Mathis, Thibaud
Labetoulle, Marc
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2024, 40 (07) : 410 - 418
[26] Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients
Avivi, Irit
Shragai, Tamir
Luttwak, Efrat
Trestman, Svetlana
Cohen, Yael C.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (03) : 367 - 370
[27] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma
Opalinska, Joanna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S425 - S425
[28] Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
Cardellino, Anna
Correll, Julia R.
Martin, Mona
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
FRONTIERS IN ONCOLOGY, 2023, 13
[29] Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report
Sabbah, Mohamed
Nguyen, Stephanie
Ouzegdouh, Maya
Choquet, Sylvain
Buob, David
Boffa, Jean Jacques
Cez, Alexandre
Garderet, Laurent
AMERICAN JOURNAL OF CASE REPORTS, 2024, 25
[30] DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma
Sunami, Kazutaka
Iida, Shinsuke
Tsukada, Nobuhiro
Fujii, Taku
Kato, Hitomi
Fukushima, Ryuichi
Wakabayashi, Satoshi
Nakano, Hirofumi
Roy-Ghanta, Sumita
Kremer, Brandon E.
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 174 - 186

← 1 2 3 4 5 →